2. Search Result
Search Result
Results for "

iron+chelator

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

3

Biochemical Assay Reagents

2

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0988
    Deferoxamine mesylate
    Maximum Cited Publications
    397 Publications Verification

    Desferrioxamine B mesylate; DFOM

    		 Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate
  • HY-B1625
    Deferoxamine
    Maximum Cited Publications
    397 Publications Verification

    Deferoxamine B; Deferriferrioxamine B; Deferrioxamine

    		 HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine
  • HY-17359
    Deferasirox
    10+ Cited Publications

    ICL 670

    		 Bacterial Ferroptosis Cancer
    Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox
  • HY-12723
    Apomorphine
    5+ Cited Publications

    (-)-Apomorphine

    		 Dopamine Receptor Monoamine Oxidase Reactive Oxygen Species (ROS) JNK ERK Amyloid-β Tau Protein MMP Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Apomorphine ((-)-Apomorphine) is a potent dopamine receptor agonist. Apomorphine also inhibit MAO-A and MAO-B. Apomorphine exerts neuroprotective effect and can relax rat corpus cavernosum. Apomorphine can inhibit ROS production, DNA fragmentation and inibit JNK and ERK1/2 phosphorylation. Apomorphine can enhance degradation of intracellular Aβ40 and Aβ42, reduces tau protein levels and inhibit MMP-9 expression. Apomorphine is a highly potent radical scavenger and iron chelator. Apomorphine can be used for the researches of dementia, parkinson's disease, alzheimer disease, breast carcinoma, and erectile dysfunction .
    Apomorphine
  • HY-18973
    Dp44mT
    5 Publications Verification

    		 Apoptosis Ferroptosis Cancer
    Dp44mT is an iron chelator with selective anticancer activity.
    Dp44mT
  • HY-114243
    DpC

    		NF-κB JNK Caspase Apoptosis Neurological Disease Cancer
    DpC is a selective, orally active iron chelator with anticancer activity. DpC acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .
    DpC
  • HY-120475
    PBT434
    2 Publications Verification

    ATH434

    		 α-synuclein Neurological Disease
    PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .
    PBT434
  • HY-131060
    CN128 hydrochloride

    CN328

    		 Ferroptosis Others
    CN128 hydrochloride (CN328) is an orally active and selective iron chelator. CN128 is used for the research of β-thalassemia .
    CN128 hydrochloride
  • HY-108260
    Deferitrin

    GT-56-252

    		 Ferroptosis Cardiovascular Disease
    Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major .
    Deferitrin
  • HY-B0988R
    Deferoxamine mesylate (Standard)

    Desferrioxamine B mesylate (Standard); DFOM (Standard)

    		 Reference Standards Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (mesylate) (Standard) is the analytical standard of Deferoxamine (mesylate). This product is intended for research and analytical applications. Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate (Standard)
  • HY-W035520
    HBED dihydrochloride

    		Biochemical Assay Reagents Others
    HBED dihydrochloride is an orally active and hexadentate phenolic aminocarboxylate iron chelator. HBED refers to N, N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid, inducing iron excretion in primates. HBED dihydrochloride has the potential to be used as an alternative to desferriamine for iron chelation therapy .
    HBED dihydrochloride
  • HY-W423191
    Maltobionic acid

    4-O-α-D-Glucopyranosyl-D-gluconic acid

    		 Nuclear Factor of activated T Cells (NFAT) Bacterial Infection Metabolic Disease
    Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H2O2)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation .
    Maltobionic acid
  • HY-124452
    Nocardamine

    Desferrioxamine E; Nocardamin

    		 Bacterial Others
    Nocardamine (Deferrioxamine E)is an iron carrier/Iron chelator with antimicrobial activity .
    Nocardamine
  • HY-114837
    HBED

    		Ferroptosis Cancer
    HBED is a potent iron chelator. HBED can be used to study transfusional iron overload .
    HBED
  • HY-120475A
    PBT434 mesylate
    2 Publications Verification

    ATH434 mesylate

    		 α-synuclein Neurological Disease
    PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .
    PBT434 mesylate
  • HY-131036
    MAO-IN-M30 dihydrochloride

    		Monoamine Oxidase Neurological Disease
    MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible MAO-A (IC50=37 nM) and MAO-B (IC50=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease . MAO-IN-M30 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MAO-IN-M30 dihydrochloride
  • HY-16912
    Petadeferitrin

    SP-420

    		 Ferroptosis Metabolic Disease
    Petadeferitrin (SP-420) is a tridentate iron chelator belonging to the class of iron chelators, with orally activity. Petadeferitrin can be used in research related to β-thalassemia .
    Petadeferitrin
  • HY-126164
    LK 614

    		Biochemical Assay Reagents Others
    LK 614 is a membrane permeable iron chelator that can be used to study the protective effects against L-Histidine (HY-N0832)-induced cell damage .
    LK 614
  • HY-N14930
    Aeruginoic acid

    		Others Cardiovascular Disease
    Aeruginoic acid is a pyochelin biosynthetic byproduct, is an iron chelator. Aeruginoic acid exhibits hypotensivee activity .
    Aeruginoic acid
  • HY-B1625R
    Deferoxamine (Standard)
    3 Publications Verification

    Deferoxamine B (Standard); Deferriferrioxamine B (Standard); Deferrioxamine (Standard)

    		 Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (Standard) is the analytical standard of Deferoxamine. This product is intended for research and analytical applications. Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine (Standard)
  • HY-W767164
    Deferiprone O-β-D-glucuronide sodium

    		Biochemical Assay Reagents Cardiovascular Disease
    Deferiprone O-β-D-glucuronide sodium is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide sodium can be used to investigate its ability to reduce iron burden in patients with β-thalassemia .
    Deferiprone O-β-D-glucuronide sodium
  • HY-101672
    Deferitazole

    FBS 0701

    		 Ferroptosis Parasite Infection
    Deferitazole (FBS 0701) is an orally active iron chelator. Deferitazole shows antimalarial activity and Can be used for study of malaria .
    Deferitazole
  • HY-17359S
    Deferasirox-d4

    		Isotope-Labeled Compounds Bacterial Ferroptosis Cancer
    Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox-d4
  • HY-17359R
    Deferasirox (Standard)

    ICL 670 (Standard)

    		 Reference Standards Bacterial Ferroptosis Cancer
    Deferasirox (Standard) is the analytical standard of Deferasirox. This product is intended for research and analytical applications. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox (Standard)
  • HY-120475B
    PBT434 free base

    ATH434 free base

    		 α-synuclein Neurological Disease
    PBT434 (ATH434) free base is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 free base can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 free base inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 free base prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 free base has the potential for the research of Parkinson’s disease (PD) .
    PBT434 free base
  • HY-100329
    CGP 65015

    		Ferroptosis Others
    CGP 65015 is an oral iron chelator, which can mobilize iron deposits.
    CGP 65015
  • HY-156776
    HAPSBC

    		Ferroptosis Others
    HAPSBC is an S-benzyl iron chelator that mobilizes intracellular 59Fe distribution .
    HAPSBC
  • HY-16913
    Desferriferrithiocin

    CGP 23841A

    		 Parasite Infection Inflammation/Immunology
    Desferriferrithiocin (CGP 23841A), a microbial iron chelator, inhibits the growth of P. falciparum in a dose dependent way .
    Desferriferrithiocin
  • HY-160078
    Deferiprone O-β-D-glucuronide

    		Biochemical Assay Reagents Metabolic Disease
    Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide can be used to investigate its ability to reduce iron burden in patients with β-thalassemia .
    Deferiprone O-β-D-glucuronide
  • HY-17359S1
    Deferasirox-13C6

    ICL 670-13C6

    		 Isotope-Labeled Compounds Ferroptosis Bacterial Cancer
    Deferasirox- 13C6 (ICL 670- 13C6) is 13C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox-13C6
  • HY-110075
    Dexrazoxane monohydrochloride

    		Apoptosis Cardiovascular Disease
    Dexrazoxane monohydrochloride is the hydrochloride of Dexrazoxane (HY-B0581). Dexrazoxane can prevent or reduce cardiac damage and is an iron chelator and apoptosis inducer. Dexrazoxane has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities and inhibits ferroptosis .
    Dexrazoxane monohydrochloride
  • HY-169298
    Ferroptosis-IN-15

    		Ferroptosis Cancer
    Ferroptosis-IN-15 (compound 12) is a potent inhibitor of ferroptosis, with the EC50s of 0.76 and 0.67 μM in A375 cells and 786-O cells, respectively.Ferroptosis-IN-15 is a potential iron chelator and radical trapping antioxidant .
    Ferroptosis-IN-15
  • HY-167814S
    Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt

    		Isotope-Labeled Compounds Biochemical Assay Reagents Metabolic Disease
    Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt is the deuterium labeled Deferiprone O-β-D-glucuronide (HY-160078). Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide shows the capability of reducing the iron burden in patients with β-thalassemia .
    Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt
  • HY-W686216
    VK-28

    		Dopamine Receptor Neurological Disease
    VK-28 is a blood-brain barrier-permeable iron chelator. VK-28 inhibits mitochondrial membrane lipid peroxidation and the iron-dependent generation of reactive hydroxyl radicals. VK-28 exhibits neuroprotective activity and protects rats against 6-OHDA-induced striatal dopaminergic damage. VK-28 can be used in studies related to Parkinson's disease .
    VK-28
  • HY-W339484
    1-Ethyl-2-methyl-3-hydroxypyrid-4-one

    		Biochemical Assay Reagents Others
    1-Ethyl-2-methyl-3-hydroxypyrid-4-one is an α-ketohydroxypyridinium iron chelator with high specificity for iron and no specific activity against other metal ions such as copper, zinc, calcium and magnesium. In rabbits with iron overload, 1-Ethyl-2-methyl-3-hydroxypyrid-4-one increased iron excretion after oral or parenteral administration.
    1-Ethyl-2-methyl-3-hydroxypyrid-4-one
  • HY-108194
    CGP 46700

    		Biochemical Assay Reagents Others
    CGP 46700 (Compound 49) is an orally active iron chelator, that exhibits high affinity for iron, removes iron from ferritin and human serum transferrin. CGP 46700 promotes iron excretion in a mouse iron overload model .
    CGP 46700
  • HY-P11638
    Mitochondrial-targeted peptide BP29

    		Mitochondrial Metabolism Neurological Disease Inflammation/Immunology
    Mitochondrial-targeted peptide BP29 is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide. Mitochondrial-targeted peptide BP29 protects human primary skin fibroblasts against ultraviolet A-induced oxidative damage to mitochondrial membranes, ATP depletion, and necrotic cell death. Mitochondrial-targeted peptide BP29 prevents hydrogen peroxide-induced oxidative stress and cytotoxicity in both healthy and Friedreich's ataxia skin fibroblasts. Mitochondrial-targeted peptide BP29 can be used for the research of Friedreich's ataxia .
    Mitochondrial-targeted peptide BP29
  • HY-P11638A
    Mitochondrial-targeted peptide BP29 acetate

    		Mitochondrial Metabolism Neurological Disease Inflammation/Immunology
    Mitochondrial-targeted peptide BP29 acetate is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide. Mitochondrial-targeted peptide BP29 acetate protects human primary skin fibroblasts against ultraviolet A-induced oxidative damage to mitochondrial membranes, ATP depletion, and necrotic cell death. Mitochondrial-targeted peptide BP29 acetate prevents hydrogen peroxide-induced oxidative stress and cytotoxicity in both healthy and Friedreich's ataxia skin fibroblasts. Mitochondrial-targeted peptide BP29 acetate can be used for the research of Friedreich's ataxia .
    Mitochondrial-targeted peptide BP29 acetate
  • HY-W718262
    Dihydroaeruginoic acid

    (Rac)-CGP 52547

    		 Antibiotic Fungal Bacterial Infection Cancer
    Dihydroaeruginoic acid ((Rac)-CGP 52547), an antifungal antibiotic, is a thiazoline iron chelator. Dihydroaeruginoic acid is the condensation product of salicylate and one cysteine residue. Dihydroaeruginoic acid chelates Fe(III), inhibits DNA replication via ribonucleotide reductase, induces G1/S cell cycle block, reduces leukemia cell clonogenic viability. Dihydroaeruginoic acid inhibits phytopathogenic fungi and bacteria, suppresses Candida albicans development, and inhibits Agrobacterium tumefaciens biofilm formation via extracellular iron sequestration. Dihydroaeruginoic acid can be used for the research of phytopathogenic fungal and bacterial infections, and leukemia .
    Dihydroaeruginoic acid
  • HY-12723R
    Apomorphine (Standard)

    (-)-Apomorphine (Standard)

    		 Reference Standards Dopamine Receptor Monoamine Oxidase Reactive Oxygen Species (ROS) JNK ERK Amyloid-β Tau Protein MMP Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Apomorphine ((-)-Apomorphine) (Standard) is the analytical standard of Apomorphine (HY-12723). This product is intended for research and analytical applications. Apomorphine is a potent dopamine receptor agonist. Apomorphine also inhibit MAO-A and MAO-B. Apomorphine exerts neuroprotective effect and can relax rat corpus cavernosum. Apomorphine can inhibit ROS production, DNA fragmentation and inibit JNK and ERK1/2 phosphorylation. Apomorphine can enhance degradation of intracellular Aβ40 and Aβ42, reduces tau protein levels and inhibit MMP-9 expression. Apomorphine is a highly potent radical scavenger and iron chelator. Apomorphine can be used for the researches of dementia, parkinson's disease, alzheimer disease, breast carcinoma, and erectile dysfunction .
    Apomorphine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: